RE: Annual report at SEDAR:22,
ONC has always stated that they would be conducting the phase II portion of the glioma trial in the United States in conjuction with a strategic partner.
where do you get this BS from? is it Brad Thompson himself or do you simply make this stuff up to sound like you, as an anonymous poster know what you are talking about?
fyi, this is the company's last official release of information on the US glio trials
https://www.integratir.com/newsrelease.asp?news=25748&ticker=T.ONC&lang=EN
3/8/2002 7:16:27 AM News Release Index
Oncolytics Biotech Inc. Files Application With U.S. FDA To Initiate Phase I/II Recurrent Glioma Trial
excerpt
CALGARY, Alberta, March 8, 2002 -- Oncolytics Biotech Inc. (TSE: ONC, NASDAQ: ONCY) (‘Oncolytics’) has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase I/II clinical trial investigating the use of REOLYSIN® to treat patients with recurrent malignant glioma, the most aggressive form of brain cancer.
i don't see anywhere in that release the mention that phase II portion of the trial will be conducted in conjunction with a partner.
and secondly, even if what you claim were accurate, why should that not be included as an objective in their latest Annual Report?
on the other hand, judging by how little official update info onc have released publicly to reassure shareholders about the glio phase I suspension in Canada, and by how many posters here declare themselves to be "in the know", it wouldn't be a total surprise if you actually got this stuff from Thompson, as part of onc's grand shareholder communication strategy.
as an apparent defender and apologist for onc management, your and their credibility might be enhanced if you just shut up with all the unsubstantiated anonymous "official" BS, until, as Thompson puts it, there is actually something materially going on at the company.